Be the first to know

Never miss an update from Alexion Pharmaceuticals. Did you know that during reporting season, the announcements from NASDAQ:ALXN often move the market?

Alexion Pharmaceuticals (NASDAQ:ALXN) Company Logo

By joining StockLight, you agree to our Terms & Conditions and Privacy Policy
Create Alert Follow ALXN

Alexion Pharmaceuticals (ALXN)

US NASDAQ:ALXN (22.8B)

103.14
+0.66 (0.64%)
4:30pm Friday Feb 21 EST
LOADING
Loading price chart..

Summary

Current Price: $103.14
52w High/Low: $94.59 - 141.86
Market Cap: 22.8B
Price/Earnings: 9.56
Dividend Yield: -
Volume/Average: 1.7M - 2M
Alexion Pharmaceuticals (NASDAQ:ALXN) Company Logo

Listed in 1996

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products... More
Alexion Pharmaceuticals (NASDAQ:ALXN) Company Logo

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.

Annual Reports

Alexion Pharmaceuticals (ALXN) 10-K Annual Report Feb 6th 2019
2019
(325kb)
Alexion Pharmaceuticals (ALXN) 10-K Annual Report Feb 8th 2018
2018
(303kb)
Alexion Pharmaceuticals (ALXN) 10-K Annual Report Mar 24th 2017
2017
(212kb)
Alexion Pharmaceuticals (ALXN) 10-K Annual Report Feb 8th 2016
2016
(1.2mb)

Dividend History

No dividends found.

Quantitative Ratios

Stock Ratios Locked
You viewed 3 companies today
Ratios will be unlocked
again tomorrow or;

Unlock these ratios,
configure alerts
and much more...

Download StockLight

All Ratios, Alerts and other features are available in our iOS and Android apps:
Download on iOS Download on Android

We are working on updating this web app to fully enable Quantitative Ratios. All other current web features including annual reports, price sensitive announcements, dividends and earnings transcripts are free to use here on our web app.
Implied Growth
53.0%
 
-0.4%
 
 
Industry Avg
ALXN

ATTRACTIVE: Alexion Pharmaceuticals exhibits an implied growth ratio which is less than the industry average for biotechnology stocks listed on the NASDAQ. ALXN calculation: 10% - ($10.70 / $103.14) = -0.4% more
Price / Book
5.2
 
2.0
 
 
Industry Avg
ALXN

ATTRACTIVE: Alexion Pharmaceuticals exhibits a price/book ratio which is less than the industry average for biotechnology stocks listed on the NASDAQ. more
Price / Earnings
19.9
 
9.6
 
 
Industry Avg
ALXN

ATTRACTIVE: Alexion Pharmaceuticals's price/earnings ratio of 9.6 is less than the industry average for biotechnology stocks listed on the NASDAQ. more
Price / Sales
23.7
 
4.6
 
 
Industry Avg
ALXN

ATTRACTIVE: Alexion Pharmaceuticals exhibits a price/sales ratio which is less than the industry average for biotechnology stocks listed on the NASDAQ. more

Company News

Is Apellis Pharmaceuticals a Buy?
February 3rd, 2020 - Motley Fool

The pre-commercial company is looking to take on a $23 billion industry leader. Promising late-stage clinical results suggest it may have a shot.

3 Top Biotech Stocks to Buy Right Now
January 30th, 2020 - Motley Fool

Here are three biotech companies with solid, revenue-driving products to add to portfolios while the price is right.

6 Industries That Are Historically Cheap, Even With the Stock Market at an All-Time High
January 22nd, 2020 - Motley Fool

Many of these industries have recently been valued at their lowest forward P/E in at least 22 years.

Here's Why Apellis Pharmaceuticals Stock Jumped as Much as 40.7% Today
January 7th, 2020 - Motley Fool

The company's lead drug candidate bested a competitor's therapy on a key endpoint in a phase 3 trial.

Apellis' Lead Drug Tops Alexion's Blockbuster Soliris in a Pivotal Late-Stage Study
January 7th, 2020 - Motley Fool

Pegcetacoplan is the first drug to beat Soliris in improving hemoglobin levels in PNH patients.

Here's Why Dicerna Pharmaceuticals Is Falling Today
December 20th, 2019 - Motley Fool

What goes up must come down. But today's tumble means relatively little for investors with a long-term mindset.

Better Buy: Vertex Pharmaceuticals vs. Alexion Pharmaceuticals
December 18th, 2019 - Motley Fool

Both of these drugmakers have solid portfolios and treatment pipelines, but savvy investors will find good reason to favor one over the other.

3 Healthcare Stocks With Heightened Expectations
October 25th, 2019 - Motley Fool

These health-related businesses managed to surprise themselves.